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Background: In patients undergoing maintenance hemodialysis (HD), hyporesponsiveness to erythropoiesis
stimulating agents (ESAs) is associated with adverse clinical outcomes. Systemic inflammation is highly prevalent in
HD patients and is associated with ESA hyporesponsiveness. Oxidative stress is also highly prevalent in HD patients,
but no previous study has determined its association with ESA response. This study assessed the association of
plasma markers of oxidative stress and inflammation with ESA resistance in patients undergoing maintenance HD.
Methods: We analyzed data from 165 patients enrolled in the Provision of Antioxidant Therapy in Hemodialysis study, a
randomized controlled trial evaluating antioxidant therapy in prevalent HD patients. Linear and mixed-effects regression
were used to assess the association of baseline and time-averaged high sensitivity F2-isoprostanes, isofurans, C-reactive
protein (hsCRP), and interleukin-6 (IL-6) with ESA resistance index (ERI), defined as the weekly weight-adjusted ESA dose
divided by blood hemoglobin level. Unadjusted models as well as models adjusted for potential confounders were
examined. Predicted changes in ERI per month over study follow-up among baseline biomarker quartiles were also
assessed.
Results: Patients with time-averaged isofurans in the highest quartile had higher adjusted mean ERI compared with
patients in the lowest quartile (β = 14.9 ng/ml; 95 % CI 7.70, 22.2; reference group <0.26 ng/ml). The highest quartiles
of hsCRP and IL-6 were also associated with higher adjusted mean ERI (β = 10.8 mg/l; 95 % CI 3.52, 18.1 for hsCRP;
β = 10.2 pg/ml; 95 % CI 2.98, 17.5 for IL-6). No significant association of F2-isoprostanes concentrations with ERI was
observed. Analyses restricted to baseline exposures and ERI showed similar results. Baseline hsCRP, IL-6, and isofurans
concentrations in the highest quartiles were associated with greater predicted change in ERI over study follow-up
compared to the lowest quartiles (P = 0.008, P = 0.004, and P = 0.04, respectively). There was no association between
baseline F2-isoprostanes quartile and change in ERI.
Conclusions: In conclusion, higher concentrations of isofurans, hsCRP and IL-6, but not F2-isoprostanes, were associated
with greater resistance to ESAs in prevalent HD patients. Further research is needed to test whether interventions that
successfully decrease oxidative stress and inflammation in patients undergoing maintenance HD improve ESA
responsiveness.
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Anemia leading to treatment with erythropoiesis-stimulating
agents (ESAs) is highly prevalent among patients with end
stage renal disease (ESRD) and both the severity of anemia
and variability in hemoglobin have been associated with
poor clinical outcomes in patients on maintenance dialysis
[1–4]. Hyporesponsiveness to ESAs – manifested as an
increase in the ESA dose requirement to maintain a con-
stant blood hemoglobin level, a drop in blood hemoglobin
on a constant ESA dose, or a failure to achieve a target
hemoglobin level on very high doses of ESAs – is also asso-
ciated with increased risk of adverse outcomes [5–7]. Fur-
thermore, ESA therapy is costly, which is further amplified
in patients with ESA hyporesponsiveness [8].
The etiology of ESA resistance in patients undergoing
maintenance hemodialysis (HD) is complex and incom-
pletely understood. One likely contributor is chronic sys-
temic inflammation, which has been found to be present in
up to 80 % of HD patients [9, 10]. Several prior studies have
identified an association between ESA resistance and blood
levels of systemic inflammatory markers such as C-reactive
protein and interleukin-6 (IL-6) [11–13]. Furthermore,
small-scale investigations of anti-inflammatory interven-
tions have suggested a potential benefit on improving ESA
responsiveness [14, 15].
Growing evidence suggests that an exaggerated oxidative
stress burden may also play a role in inducing ESA resist-
ance in patients with ESRD [16]. Plasma F2-isoprostanes,
an established measure of oxidative stress, has been found
to be up to four times higher in patients undergoing main-
tenance HD compared with healthy subjects [17]. Isofurans,
a more recently described biomarker of oxidative stress, has
been linked to increased risk for cardiovascular disease and
kidney dysfunction [18, 19]. Oxidative stress may promote
ESA resistance by increasing red blood cell fragility, de-
creasing red cell life span, and/or reducing endogenous
erythropoietin synthesis [20, 21]. No prior study has exam-
ined the association of plasma F2-isoprostanes or isofurans
with ESA resistance in HD patients. Given the poor clinical
outcomes associated with ESA hyporesponsiveness, there is
a compelling need to investigate oxidative stress as a novel
pathway leading to resistance to ESAs.
Prior studies have shown that oxidative stress and in-
flammation are synergistically linked. During an inflam-
matory response, stimulated leukocytes release superoxide
and myeloperoxidase, catalyzing oxidative injury and in
turn leading to further release of pro-inflammatory cyto-
kines and acute phase proteins through activation of the
transcription nuclear factor κB [22]. However, whether
oxidative stress and inflammation may act independently
to promote ESA hyporesponsiveness in patients with
ESRD remains unknown. The primary objective of this
study was to test the hypothesis that higher concentra-
tions of inflammatory and oxidative stress biomarkers areeach independent associate with greater resistance to
ESAs in patients undergoing maintenance HD.
Methods
Study population
Patients were identified from the Provision of Antioxidant
Therapy in Hemodialysis (PATH) study, a randomized clin-
ical trial comparing the effect of combination antioxidant
therapy with mixed tocopherols plus α-Lipoic acid (ALA)
versus matched placebo on biomarkers of inflammation
and oxidative stress in patients undergoing maintenance
dialysis [23]. Inclusion criteria for the PATH study included
ESRD receiving thrice-weekly maintenance HD for at least
120 days, age >18 years, and life expectancy >1 year. Exclu-
sion criteria included AIDS; active malignancy; recent or
anticipated kidney transplant; hospitalization over the past
30 days; vitamin E, vitamin C, or anti-inflammatory medi-
cations over the past 30 days; and history of poor adherence
to hemodialysis. Of the 353 participants randomized in the
PATH trial, we identified the 165 individuals with com-
pleted baseline measurements of F2-isoprostanes, isofurans,
high-sensitivity C-reactive protein (hsCRP), interleukin-6
(IL-6), and who were treated with an ESA at all study visits,
for inclusion in the present study. All identified patients
completed the study. Baseline patient characteristics for
participants included in the present study compared to
those excluded are presented in Additional file 1: Table S1.
The PATH trial was approved by the Western and Vander-
bilt University Medical Center institutional review boards,
and all patients provided written informed consent before
study enrollment.
Exposures
Patients underwent study visits at baseline and then
monthly for 6 months. Baseline assessment included
collection of demographic characteristics, body mass
index (BMI), comorbid conditions, etiology of ESRD,
type of vascular access, and blood for routine chemis-
tries. In addition, blood was obtained at baseline and at
month 6 for measurement of biomarkers of inflamma-
tion and oxidative stress, which represented the expo-
sures of interest. Oxidative stress was quantified by
simultaneous measurement of plasma F2-isoprostane
and isofurans by gas chromatography–mass spectrom-
etry analysis [24]. Inflammation was quantified by meas-
urement of hsCRP using ELISA (Diagnostic Systems
Laboratories, Webster, TX) and IL-6 cytokine concen-
trations also using ELISA (BioSource International,
Camarillo, CA).
Outcomes
Patients underwent blood collection for measurement of
blood hemoglobin at baseline, and at each monthly follow-
up visit. In addition, at each study visit, each patient’s last
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prior month was ascertained. The primary outcome was
the ESA resistance index (ERI), calculated as the weekly
weight-adjusted ESA dose (units per kilogram of body
weight per week) divided by the hemoglobin level (grams
per deciliter). For each patient, the ERI was calculated at
baseline, and at each monthly follow-up visit.
Statistical analyses
Baseline data were summarized, stratified by quartile of
ERI. Data are presented as mean ± standard deviation, me-
dians with interquartile ranges, and proportions as appro-
priate. Data were complete for all baseline covariates.
Scatter plots were created and Pearson’s correlation coeffi-
cients calculated to summarize the relationship among the
primary exposure inflammatory and oxidative stress bio-
markers. For both the oxidative stress markers (F2-isopros-
tanes and isofurans) and the inflammatory markers (hsCRP
and IL-6), baseline measurements of exposure variables
were grouped into quartiles. Time-averaged exposures were
generated by taking the mean of the baseline and 6-month
follow-up measurements, and were also grouped into quar-
tiles for analysis. Two main analyses were performed. First,
multivariable linear regression was performed to determine
the relationship of quartiles of baseline F2-isoprostanes, iso-
furans, hsCRP, and IL-6 with baseline ERI. Referent categor-
ies for comparisons were the lowest quartile of each baseline
exposure variable: F2-isoprostanes of <0.049 ng/ml, isofur-
ans of <0.25 ng/ml, hsCRP of <19.8 mg/l, and IL-6 of
<8.3 pg/ml. Second, the relationship between quartiles of
time-averaged oxidative stress and inflammatory markers
with mean ERI over 6-month follow-up was assessed using
a multilevel mixed-effects linear regression model with un-
structured covariance accounting for correlation among re-
peated measures within a patient. Referent categories for
comparisons were the lowest quartile of each time-averaged
exposure variable: F2-isoprostanes of <0.049 ng/ml, isofur-
ans of <0.26 ng/ml, hsCRP of <19.8 mg/l, and IL-6 of
<8.3 pg/ml.
Linear and mixed effects regressions using biomarker
quartiles as the exposure were selected for the main ana-
lysis after model diagnostics were applied to regressions
using exposures as continuous variables and substantial vio-
lations of key model assumptions were identified. Specific-
ally, plots of residuals versus fitted values were examined
and revealed both curvature and unequal variances for all
four exposures. Additionally, plots of sorted residuals versus
theoretical quantiles of the normal distribution revealed
evidence of non-normality for all four exposures. Outliers
were also identified, but deletion diagnostics did not reveal
substantially influential observations. To address these con-
cerns, log transformations of exposures and ERI were per-
formed, and regressions repeated using robust standard
errors. These changes did not satisfactorily address theviolation of linearity. Thus, for the primary analyses, regres-
sion using exposure quartiles was performed to account for
non-linearity.
For each primary analysis, three models were examined:
(1) unadjusted; (2) adjusted for potential demographic and
laboratory confounders including for age, sex, race, BMI,
etiology of ESRD, diabetes status, transferrin saturation
(serum iron/total iron binding capacity, single-pool Kt/V,
and serum parathyroid hormone); and (3) adjusted for
model 2 covariates plus log-transformed hsCRP (for ana-
lyses using oxidative stress markers as the exposures), or
log-transformed isofurans (for analyses using inflamma-
tory markers as the exposures). Additionally, for analyses
using mixed-effects linear models, study visit number and
randomly assigned treatment group were added as covari-
ates. Adjusted restricted cubic splines with four degrees of
freedom were constructed to illustrate the relationships
between baseline measures of oxidative stress and inflam-
mation with baseline ERI. Covariates included in the ad-
justed spline models were the same as for regression
model 3. For illustrative purposes, splines and 95 % confi-
dence intervals were superimposed on scatter plots of
baseline biomarker values (x-axis) and ERI (y-axis), where
each dot represents an individual patient. Three patients
with outlying values for IL-6 > 100 pg/ml were excluded
only for the purposes of illustrative spline construction.
For spline figures, a logarithmic scale was used on the x-
axis given the right-skewed distribution of oxidative stress
and inflammatory markers.
A secondary analysis was performed to determine the as-
sociation of quartiles of baseline markers of inflammation
and oxidative stress with predicted change in ERI over the
6-month study follow-up. This analysis was conducted
using a generalized estimating equation model including
interaction terms for exposure quartile and study visit, and
was conducted on cohort of 253 participants with non-
missing baseline oxidative stress and inflammatory markers,
including subjects not treated with ESA during at study
visit. Adjustment covariates were identical to primary ana-
lysis regression model 3. Statistical comparisons were made
between quartiles 4 and 1 for each biomarker exposure.
Additionally, statistical significance of the linear trend was
over all quartiles was determined.
All analyses were performed using Stata, version 11
(StataCorp LP, College Station, TX; www.stata.com).
Results
Baseline characteristics
Baseline characteristics of the study cohort, stratified by
quartile of baseline ERI are summarized in Table 1.
Compared to patients with baseline ERI <5.49, patients
with baseline ERI >19.2 were more likely to be African
American, less likely to dialyze using an arteriovenous
fistula compared with a graft, and had higher prevalence
Table 1 Baseline characteristics of study participants by quartile of ESA resistance index
ESA resistance index quartile
Characteristic Total (n = 165) <5.49 (n = 41) 5.49–< 9.67 (n =41) 9.67–< 19.2 (n =41) > = 19.2 (n =42) P-valuea
Age (yr) 58 ± 12 58 ± 11 61 ± 11 58 ± 13 59 ± 13 0.43
Male Sex, n (%) 95 (58) 22 (54) 29 (71) 23 (56) 21 (50) 0.24
Body mass index (kg/m2) 33 ± 8 35 ± 7 31 ± 7 34 (9) 32 (11) 0.12
Maintenance hemodialysis duration (mo) 35 (21, 66) 30 (21, 60) 29 (18, 49) 36 (22, 58) 48 (28, 87) 0.30
Ever smoker, n (%) 94 (57) 20 (49) 29 (71) 24 (59) 21 (50) 0.14
Pre-dialysis systolic blood pressure (mmHg) 152 ± 24 150 ± 23 151 ± 22 154 ± 24 154 ± 27 0.77
Randomized to PATH study treatment, n (%) 78 (47) 20 (49) 20 (49) 18 (44) 20 (48) 0.97
Race, n (%) 0.18
White 59 (36) 15 (37) 19 (46) 16 (39) 9 (21) -
African American 102 (62) 25 (61) 22 (54) 23 (56) 32 (76) -
Asian 1 (1) 1 (2) 0 (0) 2 (5) 0 (0) -
Other 3 (2) 0 (0) 0 (0) 0 (0) 1 (2) -
Type of vascular access, n (%) 0.74
Fistula 106 (64) 27 (66) 28 (68) 28 (68) 23 (55) -
Graft 50 (30) 12 (29) 11 (27) 11 (27) 16 (38) -
Catheter 9 (6) 2 (5) 2 (5) 2 (5) 3 (7) -
Cause of ESRD, n (%) 0.83
Diabetes 69 (42) 17 (41) 14 (34) 22 (54) 16 (38) -
Hypertension 66 (40) 16 (39) 17 (41) 14 (34) 19 (45) -
Glomerulonephritis 11 (7) 4 (10) 3 (7) 2 (5) 2 (5) -
Polycystic kidney disease 7 (4) 1 (2) 3 (7) 2 (5) 1 (2) -
Other 12 (7) 3 (7) 4 (10) 1 (2) 4 (10) -
Comorbid disease, n (%)
Diabetes 96 (58) 24 (58) 22 (54) 27 (66) 23 (55) 0.67
History of cardiovascular disease 83 (50) 16 (39) 22 (54) 20 (49) 25 (59) 0.29
Medication use
ESA dose (units/kg/week) 117 (66, 217) 41 (25, 53) 88 (72, 100) 157 (132, 182) 298 (242, 389) <0.001
IV iron dose (mg/week) 50 (25, 62.5) 50 (25, 62.5) 50 (0, 75) 62.5 (25, 62.5) 62.5 (25, 100) 0.12
Blood laboratory results at enrollment
spKt/V 1.4 ± 0.4 1.4 ± 0.5 1.4 ± 0.2 1.4 ± 0.6 1.4 ± 0.3 0.91
Albumin (mg/dl) 3.9 ± 0.3 4.0 ± 0.3 4.1 ± 0.2 4.0 ± 0.3 3.9 ± 0.3 0.01
Hemoglobin (mg/dl) 11.6 ± 1.1 11.9 ± 0.8 11.7 ± 0.9 11.8 ± 1.1 11.1 ± 1.3 0.02
Parathyroid hormone (pg/dl) 331 (192, 520) 410 (234, 613) 326 (196, 430) 264 (185, 457) 388 (189, 649) 0.28
Iron (ug/dl) 69.7 ± 21.5 64.8 ± 22.8 67.2 ± 20.7 55.9 ± 20.9 50.7 ± 17.7 <0.001
Transferrin saturation (%) 24 ± 8.7 25 ± 10 28 ± 8.8 24 ± 7.0 23 ± 7.0 0.002
Ferritin (ng/dl) 512 (375, 767) 512 (420, 835) 608 (353, 778) 464 (345, 652) 604 (358, 759) 0.25
Values for categorical variables given as n (%); values for continuous variables given as mean ± SD or median (IQR)
ESA Erythropoesis stimulating agent, IV intravenous, hsCRP high-sensitivity C-reactive protein, IL-6 Interleukin 6
aP-value from test for heterogeneity among groups
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duration. Additionally, patients with higher baseline ERI
had lower serum iron and lower transferrin saturation.
Baseline F2-isoprostane concentrations were positively
correlated with hsCRP (r = 0.30) (Fig. 1). In contrast,isofurans concentrations were only very weakly corre-
lated with hsCRP (r = 0.09), and were not correlated with
IL-6 levels (r = 0.01). Plots illustrating the relationship of
F2-isoprostanes with isofurans and hsCRP with IL-6 are
shown in Additional file 1: Figure S1.
Fig. 1 Correlation of baseline F2-isoprostanes and isofurans with baseline hsCRP and IL-6 in maintenance hemodialysis patients. Panels a and
b - F2-isoprostanes and inflammatory markers; Panels c and d - Isofurans and inflammatory markers
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Table 2 shows the associations of baseline F2-isopros-
tanes and isofurans with baseline ERI. In unadjusted
analyses, patients in the highest quartile of isofurans
concentrations (>0.71 ng/ml) had significantly higher
ERI compared to patients with concentrations <0.25 ng/ml
(β = 7.49; 95 % CI 1.14, 13.8; P = 0.02). This association per-
sisted following adjustment for demographic variables and
transferrin saturation (Model 2), as well as following
further adjustment for hsCRP (Model 3). Additionally,
patients in the second quartile (0.25–< 0.45 ng/ml) but
not the third quartile (0.45–< 0.73 ng/ml) also had sig-
nificantly higher ERI relative to those in the lowest
quartile. This association remained significant across
adjustment models, though the significance was attenu-
ated with greater adjustment. In contrast, no significant
association between quartile of F2-isoprostanes and ERI
was observed, regardless of level of adjustment. Figure 2
illustrates the continuous adjusted relationships between
baseline concentrations of F2-isoprostanes and isofurans
with ERI.Table 3 shows the associations of time-averaged markers
of oxidative stress with mean ESA resistance over follow-
up, using linear mixed-effects models. The results of the
analyses using time-averaged isofurans as the exposure vari-
able were not substantially different than those using only
the baseline measurements, with the second and highest
quartiles of isofurans concentration associated with higher
mean ERI (reference group: patients with time-averaged iso-
furans concentration <0.26 ng/ml), regardless of the specific
adjustment model. In contrast to the analyses using baseline
measurements, patients with time-averaged F2-isoprostanes
in the highest quartile had significantly higher mean ERI
compared to patients with concentrations <0.049 ng/ml
(β = 9.82; 95 % CI 1.78, 17.9; P = 0.02) with adjustment for
baseline demographic and laboratory variables. However,
following full adjustment for potential confounders includ-
ing for hsCRP (Model 3), this association was no longer
significant.
Comparing predicted change in ERI per month over six-
month study follow-up, patients with baseline isofurans
concentrations >0.73 ng/ml had a significantly higher
Table 2 Association of quartiles of baseline markers of oxidative stress with baseline ESA resistance index (ERI) in maintenance
hemodialysis patients
Concentration Model 1a Model 2b Model 3c
β 95 % CI P-valued β 95 % CI P-valued β 95 % CI P-valued
F2-Isoprostanes (ng/ml) <0.049 Reference - - Reference - - Reference - -
0.049–< 0.063 −0.54 −6.06, 4.98 0.85 −3.02 −9.13, 3.09 0.33 −2.87 −9.09, 3.35 0.36
0.063–< 0.087 −2.03 −6.10, 2.04 0.33 −2.21 −7.95, 3.52 0.45 −2.40 −7.94, 3.14 0.39
≥0.087 5.04 −2.00, 12.1 0.16 8.00 −1.53, 17.5 0.10 6.44 −2.54, 15.4 0.16
Isofurans (ng/ml) <0.25 Reference - - Reference - - Reference - -
0.25–< 0.45 6.67 1.55, 11.8 0.01 5.61 0.24, 10.98 0.04 5.29 0.003, 10.6 0.050
0.45–< 0.73 4.42 −0.31, 9.25 0.07 3.99 −1.74, 9.74 0.17 2.41 −3.52, 8.34 0.42
≥0.73 7.49 1.14, 13.8 0.02 9.45 1.49, 17.4 0.02 9.10 1.25, 16.9 0.02
ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein
a Unadjusted
b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity),
Kt/V, and serum parathyroid hormone
c Adjusted for Model 2 covariates plus hsCRP
d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker
Fig. 2 Scatter plots and adjusted restricted cubic splines illustrating
relationship of baseline F2-isoprostanes and isofurans with baseline ESA
responsiveness index (ERI) in maintenance hemodialysis patients. Panel a
F2-isoprostanes; b Isofurans. Shaded area represents 95 % confidence
interval. P-value from multivariable linear regression comparison of quartile
4 to quartile 1, adjustment covariates as per regression model 3
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isofurans <0.25 n/gml (6.26 ng/ml/month; 95 % CI 0.19,
12.33; P = 0.04) (Table 4). In contrast, there was no signifi-
cant difference among quartiles of baseline F2-isoprostanes
concentrations with respect to monthly ERI change. Nei-
ther oxidative stress marker was associated with a linear
trend in ERI change across quartiles.
Association of markers of inflammation with ERI
In unadjusted analyses, similar to the observed associa-
tions between isofurans and ERI, patients with baseline
hsCRP ≥101 mg/l had higher mean baseline ERI com-
pared with patients with hsCRP <19.8 mg/dl (β = 8.45;
95 % CI 1.63, 15.3; P = 0.01) (Table 5). Conversely, pa-
tients with baseline hsCRP falling into the middle two
quartiles did not have significantly higher baseline ERI
compared with patients with hsCRP in the lowest quar-
tile. Patients with baseline IL-6 concentrations in the
highest quartile of ≥20.9 pg/ml, but not those with mea-
surements in the middle two quartiles, had significantly
higher ERI compared to patients with IL-6 < 8.3 pg/ml
(β = 9.15; 95 % CI 2.78, 15.5; P = 0.005). Upon adjust-
ment for demographic factors and baseline transferrin
saturation, and further adjustment for oxidative stress as
measured by isofurans concentration, these observed as-
sociations remained statistically significant for IL-6, but
were only of borderline significance for hsCRP (Table 5).
Table 6 presents the results of analyses assessing the
association of time-averaged markers of inflammation
with mean ERI over follow-up, using linear mixed-
effects models. For time-averaged IL-6, the results were
substantially similar to the analyses using only baseline
measurements, with higher mean ERI observed in pa-
tients with IL-6 in the highest quartile, regardless of the
Table 3 Association of quartiles of time-averaged markers oxidative stress with mean ESA resistance index (ERI) over 6-month
follow-up in maintenance hemodialysis patients
Concentration Model 1a Model 2b Model 3c
β 95 % CI P-valued β 95 % CI P-valued β 95 % CI P-valued
F2-Isoprostanes (ng/ml) <0.049 Reference - - Reference - - Reference - -
0.049–< 0.066 2.78 −3.68, 9.24 0.40 4.65 −2.89, 12.2 0.23 4.61 −2.74, 11.9 0.22
0.066–< 0.086 4.41 −2.05, 10.9 0.18 7.60 0.01, 15.2 0.050 7.31 −0.10, 14.7 0.05
≥0.086 6.18 −0.28, 12.6 0.06 9.82 1.78, 17.9 0.02 7.47 −0.58, 15.5 0.07
Isofurans (ng/ml) <0.26 Reference - - Reference - - Reference - -
0.26–< 0.44 10.46 4.24, 16.7 0.001 8.17 1.29, 15.0 0.02 7.33 0.55, 14.1 0.03
0.44–< 0.79 5.79 −0.44, 12.0 0.07 5.05 −2.18, 12.3 0.17 5.49 −1.62, 12.6 0.13
≥0.79 11.5 5.36, 17.7 <0.001 16.4 9.10, 23.7 <0.001 14.9 7.70, 22.2 <0.001
ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein
a Unadjusted
b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity),
Kt/V, serum parathyroid hormone, study visit, and treatment assignment
c Adjusted for Model 2 covariates plus hsCRP
d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker
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patients with marker concentrations in the highest quartile
had significantly higher mean ERI not only in the un-
adjusted model, but also in the fully adjusted model (β =
10.8 mg/l; 95 % CI 3.52, 18.1; P = 0.004).
Figure 3 illustrates the continuous unadjusted relation-
ship between hsCRP and IL-6 with ERI. Examination of
the restricted cubic splines further supported the use of
quantile regression rather than continuous linear regres-
sion, as the relationship between inflammatory markers
and ERI was curvilinear. Similar to the results of the re-
gression analyses, an association between greater inflam-
mation and higher ERI was evident only at higher
concentrations of hsCRP and IL-6.
Comparing predicted change in ERI per month over
six-month study follow-up, patients with baseline hsCRP
concentrations >101 mg/l had a significantly higher pre-
dicted monthly ERI increase compared to patients with
hsCRP <19.8 mg/l (8.27 mg/l/month; 95 % CI 2.17,
14.38; P = 0.008) (Table 4). Similarly, patients withTable 4 Comparison of adjusted change in ESA resistance index pe
and inflammatory marker quartiles
Change in ESA Resistance Index per Month
Marker Quartile 1 Quartile 2 Qua
F2-Isoprostanes (ng/ml/month) .76 (.07,1.45) 2.54 (−3.64,8.73) 1.65 (−4
Isofurans (ng/ml/month) .65 (−.02,1.32) 6.87 (.83,12.92) 2.41 (−3
hsCRP (mg/l/month) .15 (−.53,.84) 2.15 (−3.96,8.27) 4.99 (−1
IL-6 (pg/ml/month) .52 (−.15,1.19) 2.89 (−3.05,8.84) 2.7 (−3.3
a Adjusted for age, sex, race, body mass index, etiology of end stage renal disease,
Kt/V, serum parathyroid hormone, study visit, and treatment assignment
b P-value for trend over biomarker quartilesbaseline IL-6 in the highest quartile had significantly
greater monthly change in ERI over follow-up compared
to patients in the lowest quartile (P = 0.004). Neither in-
flammatory marker was associated with a linear trend in
ERI change across quartiles.
Sensitivity analysis
Two sets of sensitivity analyses were performed. In the
first set, the study cohort was expanded to include partici-
pants of PATH who had one or more study visits during
which they were untreated with ESAs. Inclusion of these
additional participants increased the total number of sub-
jects from 165 to 253. Linear regressions assessing the as-
sociation between baseline biomarker concentrations and
baseline ERI, and linear mixed-effects regressions asses-
sing the association between time-averaged exposures and
mean ERI were repeated with the expanded cohort. The
results of these analyses were similar to those obtained in
the primary analysis (Additional file 1: Tables S2–S5). On
exception was that patients with baseline IL-6 in ther month over study follow-up among baseline oxidative stress
a




.62,7.93) 5.95 (−.45,12.35) 0.07 0.63
.74,8.56) 6.26 (.19,12.33) 0.04 0.99
.12,11.09) 8.27 (2.17,14.38) 0.008 0.59
5,8.75) 8.79 (2.83,14.75) 0.004 0.83
diabetes status, transferrin saturation (serum iron/total iron binding capacity),
Table 5 Association of quartiles of baseline markers of inflammation with baseline ESA resistance index (ERI) in maintenance
hemodialysis patients
Concentration Model 1a Model 2b Model 3c
β 95 % CI P-valued β 95 % CI P-valued β 95 % CI P-valued
hsCRP (mg/l) <19.8 Reference - - Reference - - Reference - -
19.8–<45.7 3.32 −1.44, 8.08 0.17 2.92 −2.42, 8.25 0.28 3.49 −1.98, 8.95 0.21
45.7–<101 3.34 −1.59, 8.27 0.18 4.98 −1.27, 11.24 0.12 4.93 −1.32, 11.2 0.12
≥101 8.45 1.63, 15.3 0.02 7.84 −0.38, 16.1 0.06 7.40 −0.04, 14.8 0.05
IL-6 (pg/ml) <8.3 Reference - - Reference - - Reference - -
8.3–<13.1 2.20 −2.38, 6.78 0.34 2.49 −2.81, 7.80 0.35 3.78 −2.02, 9.57 0.19
13.1–<20.9 5.17 0.70, 9.64 0.02 2.59 −3.42, 8.59 0.39 2.36 −3.44, 8.16 0.42
≥20.9 9.15 2.78, 15.5 0.005 8.00 0.52, 15.5 0.04 7.82 0.86, 14.8 0.03
ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
ESA erythropoeisis stimulating agent, hsCRP high-sensitivity C-reactive protein, IL-6 Interleukin-6
a Unadjusted
b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity),
Kt/V, and serum parathyroid hormone
c Adjusted for Model 2 covariates plus isofurans
d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker
Rivara et al. BMC Nephrology  (2015) 16:79 Page 8 of 12highest quartile had significantly higher ERI compared to
those in the lowest quartile only in an unadusted analysis;
following full adjustment, this association was no longer
presents (Additional file 1: Table S4).
In the second set of sensitivity analyses, only patients
who were treated with ESA at each study visit, and who
were assigned to the control group in the PATH trial
were included in the study cohort. This restricted cohort
to 87 participants was then analyzed using linear mixed
effects regression to determine the association of time-
averaged inflammatory and oxidative stress exposures
with ERI. This approach was employed to eliminate the
possible impact of antioxidant treatment on the time-
averaged exposures. The results of this set of analysesTable 6 Association of quartiles of time-averaged markers of inflam
follow-up in maintenance hemodialysis patients
Concentration Model 1a Mo
β 95 % CI P-valued β
hsCRP (mg/l) <22.1 Reference - - Re
22.1–<53.4 −1.15 −7.51, 5.21 0.72
53.4–<117 2.29 −4.07, 8.64 0.48
≥117 7.53 1.21, 13.8 0.02
IL-6 (pg/ml) <9.4 Reference - - Re
9.4–<14.1 2.01 −4.26, 8.28 0.53
14.1–<20.8 6.39 0.11, 12.7 0.05
≥20.8 10.7 4.42, 16.9 0.001
ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the
ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein, IL-6
a Unadjusted
b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease,
Kt/V, serum parathyroid hormone, study visit, and treatment assignment
c Adjusted for Model 2 covariates plus isofurans
d P-values obtained from comparing regression coefficients to coefficient for lowestare reported in Additional file 1: Tables S6 and S7. Pa-
tients with time-averaged hsCRP in the top two quartiles
had significantly greater mean ERI compared to those in
the lowest quartile (β = 11.9 mg/l; 95 % CI 2.91, 20.8;
P = 0.01). There were no significant associations between
quartile of IL-6, F2-isoprostanes or isofurans and ERI.
Discussion
In this study examining the association of markers of in-
flammation and oxidative stress on ESA resistance in pa-
tients undergoing maintenance dialysis, we found that
higher concentrations of hsCRP, IL-6 and isofurans, but
not F2-isoprostanes, were associated with increased
resistance to ESAs, as measured by ERI. Thesemation with mean ESA resistance index (ERI) over 6-month
del 2b Model 3c
95 % CI P-valued β 95 % CI P-valued
ference - - Reference - -
3.09 −5.21, 11.4 0.47 4.27 −3.56, 12.1 0.29
4.76 −3.26, 12.8 0.25 4.65 −2.89, 12.2 0.23
11.2 3.41, 18.9 0.005 10.8 3.52, 18.1 0.004
ference - - Reference - -
2.29 −4.96, 9.54 0.54 2.30 −4.54, 9.14 0.51
4.43 −2.88, 11.7 0.24 3.07 −3.86, 10.0 0.39
11.4 3.69, 19.0 0.004 10.2 2.98, 17.5 0.006
baseline hemoglobin level (g/dl)
Interleukin-6
diabetes status, transferrin saturation (serum iron/total iron binding capacity),
quartile of each inflammatory marker
Fig. 3 Scatter plots and adjusted restricted cubic splines illustrating
relationship of baseline high sensitivity C-reactive protein (hsCRP) and
interleukin-6 (IL-6) with baseline ESA responsiveness index (ERI) in
maintenance hemodialysis patients. Panel a hsCRP; b IL-6. Shaded area
represents 95 % confidence interval. P-value from multivariable linear
regression comparison of quartile 4 to quartile 1, adjustment covariates
as per regression model 3
Rivara et al. BMC Nephrology  (2015) 16:79 Page 9 of 12associations were evident in unadjusted models, and also
following adjustment for potential demographic and la-
boratory confounders. Additionally, these associations
were not linear, with higher ERI only observed for pa-
tients with inflammatory biomarkers in the top quartile,
and for patients with isofurans in the second and fourth
but not the third quartile. Finally, the association be-
tween increased concentrations of isofurans and ERI
remained significant following adjustment for hsCRP,
and that for the markers of inflammation and ERI
remained significant with adjustment for isofurans. This
observation suggests possible distinct biological mecha-
nisms leading from inflammation versus oxidative stress
to ESA resistance.
Multiple mechanisms may explain how systemic inflam-
mation leads to inhibition of erythropoiesis and thus to re-
sistance to ESAs in patients undergoing maintenance HD.
Patient with ESRD have many contributory factors tosystemic inflammation, including uremic toxin buildup, di-
alysate microcontamination, exposure to indwelling cathe-
ters and synthetic grafts, and high prevalence of comorbid
diabetes and atherosclerotic disease [25]. Inflammation has
in turn been shown to lead to activation of macrophages
with removal of circulating erythrocytes, down-regulation
of erythropoietin receptors, and dysregulated cell signaling
following activation of the erythropoietin receptor [26, 27].
Additionally, inflammatory cytokines have been demon-
strated to decrease erythropoietin production, suppress
proliferation of red cell precursors in the bone marrow, and
decrease release of mature erythrocytes into the circulation
[28–30].
The data on the contribution of oxidative stress to anemia
in patients with ESRD undergoing maintenance dialysis are
far more limited. Oxidative stress has been shown to be as-
sociated with anemia through downregulation of erythropoi-
etin synthesis, decreased red cell production, and increased
erythrocyte fragility. In particular, human erythrocyte nitric
oxide synthesis and production of peroxynitrite are activated
by oxidative stress leading to upregulation of superoxide dis-
mutase, increased erythrocyte membrane rigidity, and short-
ening of red cell lifespan [21, 31]. In clinical studies, lipid
peroxidation of the erythrocyte cell membrane has been
positively associated with markers of red cell destruction,
and with resistance to administered ESAs in patients under-
going maintenance HD [20]. Additionally, elevated circulat-
ing 8-hydroxy-2’-deoxyguanosine, a product of oxidized
DNA, has been associated with greater ESA resistance in
HD patients [32]. Furthermore, oxidative stress activates cat-
ionic erythrocyte membrane channels permeable to ionic
calcium, anionic channels permeable to chloride ions, and
apoptotic caspases, all of which may lead to upregulation of
programmed erythrocyte cell death [33, 34]. In our study,
we found that isofurans were poorly correlated with both
hsCRP and IL-6, and there remained a predictive relation-
ship between isofurans and ERI even after adjustment for
hsCRP as a biomarker of inflammation. These observations
provide evidence that the pathway leading from oxidative
stress to ESA resistance is likely distinct from the more
well-characterized pathway linking inflammation with ESA
resistance. Our findings are in line with those of other stud-
ies that have identified pathways leading to ESA resistance
that are independent of inflammation. Kalim et al. have re-
cently demonstrated the association of non-enzymatic car-
bamylation of serum albumin with erythropoietin resistance
in ESRD patients, even after adjustment for serum markers
of systemic inflammation [35].
In our study, we found an unexpected non-linear rela-
tionship between quartiles of isofurans and ESA resistance
that was particular notable in the time-averaged analyses.
Specifically, we observed higher ERI in patients with isofur-
ans falling not only in the highest quartile, but also in the
middle-low quartile. No significant difference was found
Rivara et al. BMC Nephrology  (2015) 16:79 Page 10 of 12among patients with isofurans in the third quartile. Cer-
tainly one possible explanation for this finding is a statistical
one, namely absence of a sufficient sample size to provide
adequate power to detect a difference of 5.5 ng/ml in iso-
furans concentration between the first and third quartiles.
Indeed, the β coefficient estimates for the first and third
quartiles were 7.3 versus 5.5 ng/ml, numerically quite simi-
lar. Alternatively, a true non-linear relationship may exist.
Studies of DNA mutagens that act via oxidative stress have
shown non-linear dose-effect relationships, with multiple
threshold “plateaus” that correspond to the action of cellu-
lar defense mechanisms such as reactive oxygen species
scavengers and antioxidant enzymes [36]. Similarly, a non-
linear relationship between cigarette smoke exposure and
cardiovascular risk has also been demonstrated [37]. Thus,
in our study, stepping from the second to the third quartile
of oxidative stress could theoretically trigger an additional
protective mechanism that may reinstate the balance betew-
een oxidants and antioxidants. In the case of ESA resistance
in patients undergoing maintenance HD, such a trigger
could partially restore ESA responsiveness. Stepping to the
highest level of oxidative stress may overwhelm cellular
defense mechanisms leading to ESA resistance. Given that
such an explanation remains speculative, further basic and
translational research is needed to elucidate the connection
between oxidative stress, anemia and ESA resistance.
We observed that high concentrations of isofurans but
not F2-isoprostanes were associated with higher ERI. This
difference in the predictive role of these two products of free
radical-induced peroxidation of arachadonic acid on the de-
gree of ESA resistance was an unexpected finding. Prior
studies have shown that relative formation of lipid peroxida-
tion products, including F2-isoprostanes and isofurans, is
profoundly influenced by ambient oxygen concentration
[38]. In particular, as oxygen concentration increases, F2-
isoprostanes formation becomes disfavored, and isofurans
formation becomes more favored. In highly oxygenated tis-
sues, such as the central nervous system and the kidneys,
isofurans concentrations can exceed F2-isoprostanes levels
by greater than two-fold [38]. At the cellular level, elevated
levels of reactive oxygen species, as have been demonstrated
in ESRD, have been shown to be associated with impaired
mitochondrial respiration [39, 40]. Impaired mitochondrial
function with blockade of the electron transport chain may
then lead to impaired oxygen utilization and buildup of
intracellular oxygen molecules with concomitant increased
intracellular oxygen concentrations. Independent of blood
hemoglobin levels, such increased oxygen concentra-
tions favor isofurans production over F2-isoprostanes
production. Furthermore, impaired signaling along the
erythropoietin axis is associated with decreased mitochon-
drial biogenesis, and greater mitochondrial dysfunction,
also leading to impaired oxygen utilization, buildup of
oxygen tension, and subsequent predominance ofisofurans [41–43]. These observations together are one
possible explanation for why we observed an association
between ERI and isofurans, but not F2-isoprostanes. How-
ever, this explanation is theoretical and further research is
needed to determine the cellular pathways leading to dif-
ferential oxidative stress biomarker production.
Our study has multiple strengths. The PATH trial is the
largest published trial of antioxidant therapy conducted to
date in patients undergoing maintenance HD. All analyzed
patients thus had excellent follow-up and were well char-
acterized. Additionally, the lipid peroxidation biomarkers
(F2-isoprostanes and isofurans) were analyzed at a refer-
ence quality laboratory using gas chromatography/mass
spectrometry, thus providing gold standard measures of
oxidative stress. Furthermore, repeated measurements of
erythropoietin dose response over a 6-month period
allowed use of a linear mixed-effects model to incorporate
longitudinal data on ESA resistance, increasing the reli-
ability of the observed associations.
Our study also has some limitations. First, though we
identified a number of important associations with ESA
resistance, it is unclear whether these are causal. Second,
the use of data from a clinical trial population may de-
crease the generalizability of the observed findings. Third,
though the results from the PATH trial showed no signifi-
cant impact of antioxidant treatment status on ESA resist-
ance over study follow-up, it is possible that treatment
status may impact the association between inflammatory
or oxidative stress markers and ERI. We have attempted
to account for this by controlling for trial group assign-
ment in our multivariable regression models, by the possi-
bility of residual confounding remains. Fourth, patients
enrolled in the PATH trial were slightly younger and had
a higher mean BMI than the general United States ESRD
population, which may limit generalizeabilty. Recent work,
however, has shown that age does not predict ESA re-
sponse in either pediatric or adult patients undergoing
dialysis [44]. Additionally, though BMI is associated with
ESA dose in HD patients, the correlation is weak, and cal-
culation of ERI incorporates body weight [45, 46]. Add-
itionally, we have adjusted for both age and BMI in our
final adjustment models. A final limitation is that given
the observational nature of our study, there remains the
possibility of residual confounding by unmeasured vari-
ables on the association between the measured biomarkers
inflammation and oxidative stress with ESA resistance.
Conclusions
In conclusion, we found that in patients undergoing
maintenance HD, higher concentrations of isofurans,
hsCRP, and IL-6 but not F2-isoprostanes, were associated
with increased resistance to erythropoiesis-stimulating
agents. The association between isofurans and ERI per-
sisted even after adjustment for levels of inflammation.
Rivara et al. BMC Nephrology  (2015) 16:79 Page 11 of 12These findings support that oxidative stress is an import-
ant contributor to ESA resistance in the ESRD population,
and suggest a pathway independent of systemic inflamma-
tion. Future studies should test whether interventions that
successfully decrease oxidative stress and inflammation in
patients undergoing maintenance dialysis lead to reduc-
tions in ESA dose requirements.
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